Navigation Links
Data from Jazz Pharmaceuticals' First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences
Date:10/14/2009

PALO ALTO, Calif., Oct. 14 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that data from the company's first Phase III clinical trial of sodium oxybate (JZP-6) for the treatment of fibromyalgia will be presented next week during the American College of Rheumatology 2009 Annual Meeting (ACR) in Philadelphia, Pennsylvania and also in November during the US Psychiatric and Mental Health Congress (US Psych Congress) in Las Vegas, Nevada.

  • At ACR on October 20, 2009, I. Jon Russell, MD, PhD, Associate Professor of Medicine in the Division of Clinical Immunology and Rheumatology and Director, University Clinical Research Center at The University of Texas Health Science Center at San Antonio, will present a poster entitled, "Effect of Sodium Oxybate on Pain, Functionality, PGIc, & Composite Scores in Fibromyalgia - Results from a Phase 3 Controlled Trial". The poster will be presented in the 9:00 am - 11:00 am poster session.
  • Also at ACR on October 20, 2009, Philip J. Mease, MD, Clinical Professor at the University of Washington School of Medicine in Seattle and Chief of Rheumatology Clinical Research at the Swedish Hospital Medical Center, will present a poster entitled, "Sodium Oxybate Improves Fatigue, Sleep Disturbance, and PGIc in Fibromyalgia - Results from a Phase 3, 14-Week Controlled Trial". The poster will be presented in the 9:00 am - 11:00 am poster session.
  • At US Psych Congress on November 2, 2009, Stephen S. Flitman, MD, Medical Director at 21st Century Neurology, a division of Xenoscience, will present a poster entitled, "Efficacy and Safety of Sodium Oxybate in Fibromyalgia: A 14-week, Randomized, Double-blind, Controlled Trial". The poster will be presented in the 3:45 pm - 6:45 pm poster session.

Jazz Pharmaceuticals has completed two Phase III pivotal clinical trials of JZP-6, with positive results in both studies. Jazz Pharmaceuticals is working to submit a New Drug Application for sodium oxybate for the treatment of fibromyalgia to the U.S. Food and Drug Administration by the end of 2009.

About Sodium Oxybate

Sodium oxybate is the sodium salt form of gamma-hydroxybutyrate, an endogenous neurotransmitter and metabolite of GABA. While the precise mechanism of action is unknown, the effects may be mediated in part through interaction with GABA(B) and GHB receptors. Sodium oxybate is the active ingredient in XYREM®, approved by the FDA for the treatment of excessive daytime sleepiness and cataplexy (the sudden loss of muscle tone) in adult patients with narcolepsy. The American Academy of Sleep Medicine recommends sodium oxybate as a standard of care for the U.S. Food and Drug Administration-approved indications. It is also approved by the European Medical Evaluation Agency for the treatment of narcolepsy with cataplexy in adult patients. Most commonly reported adverse drug reactions in narcolepsy patients are dizziness, nausea and headaches. Sodium oxybate has the potential to induce respiratory depression and neuropsychiatric events. Sodium oxybate has not been evaluated by regulators for the treatment of fibromyalgia and is not approved for this use.

About Fibromyalgia

Fibromyalgia, a chronic condition characterized by widespread pain, affects 0.5% - 5% of adults worldwide. Fibromyalgia is believed to be a central nervous system condition, resulting from neurological changes in how the brain perceives and responds to pain. In addition to pain, the main symptoms are fatigue, disturbed sleep and morning stiffness. The exact causes of fibromyalgia are unknown. It may be triggered by physical trauma, emotional stress, chronic pain or infection. Genetics, neurochemicals that affect pain modulation, neurohormones and sleep physiology abnormalities are thought to play a role. Research also has suggested a relationship between sleep and pain. Fibromyalgia patients experience a high prevalence of sleep problems, including a reduction in non-restorative or deep sleep.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. For further information please see www.jazzpharmaceuticals.com.

SOURCE Jazz Pharmaceuticals, Inc.


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Timm Medical Technologies and Ferring Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Prosed(R) DS
2. China Yongxin Pharmaceuticals Inc. Announces Second Quarter 2009 Financial Results
3. VIA Pharmaceuticals Receives Favorable Hearing Decision From NASDAQ
4. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
5. Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives
6. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
7. Onyx Pharmaceuticals to Acquire Proteolix, Inc.
8. Onyx Pharmaceuticals Announces Investor Teleconference and Webcast
9. ADVENTRX Pharmaceuticals Announces Closing of Financing
10. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
11. Endo Pharmaceuticals to Announce Third Quarter 2009 Financial Results on October 29, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 21, 2017 Mass Spectrometer Market: Overview ... This report on mass spectrometer ... prospects of the market globally. The stakeholders of ... the manufacture and commercialization of various mass spectrometer ... planning to enter this market. This report comprises ...
(Date:2/21/2017)... -- Luminex Corporation (NASDAQ: LMNX ) (the "Company") today ... of a quarterly cash dividend to its shareholders, the first ... payable on April 14, 2017 to shareholders of record as ... The board of directors intends for the Company ... holders of its common stock, representing a planned annual dividend ...
(Date:2/21/2017)... Feb. 21, 2017  Global health services company Cigna ... ® for breast reconstruction surgery and Dermacell ... an advanced acellular dermal matrix developed by LifeNet Health ... NVDQ ) "We are proud ... health-care payers to review the growing base of evidentiary ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... Robins ... Clinic in Durant, Oklahoma, on Feb. 21. , The celebration began with a ... members, clinic employees, the construction team and tribal leadership. , Choctaw Nation ...
(Date:2/21/2017)... ... ... Doctors on Liens has announced the addition of Mendonca Spine Care Center ... network of doctors in Central and Northern California. Dr. Mendonca specializes in personal injury ... pain, neck pain, hip and knee pain, and headaches. Specializing in non-surgical, spinal ...
(Date:2/21/2017)... ... February 21, 2017 , ... Ray Insurance Agencies, a Dallas area firm providing ... is embarking on a six month charity event aimed at raising local support and ... is one of the deadliest diseases in America; more than 7.5 million people die ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... announced the further expansion of its eHealth App xChange™, providing clinical researchers ... of Bioclinica’s extensive and growing eHealth platform. Applications that enable patient-centered clinical ...
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... ... with over 50,000 participants. The connected care demonstration spanned multiple health information ... National Coordinator, roughly 30% of providers have no Health Information Exchange outside of ...
Breaking Medicine News(10 mins):